Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Dermatologic 1Breast 1

Conditions

Sarcoma 172Glioblastoma 72Gliosarcoma 70Brain Neoplasms 41Osteosarcoma 40Neoplasms 40Astrocytoma 38Recurrence 35Melanoma 33Oligodendroglioma 32Gastrointestinal Stromal Tumors 31Breast Neoplasms 31Glioma 30Lymphoma 29Dendritic Cell Sarcoma, Interdigitating 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Neoplasm Metastasis 28Central Nervous System Neoplasms 27Burkitt Lymphoma 26Bone Neoplasms 26Ovarian Neoplasms 25Colorectal Neoplasms 24Neuroblastoma 22Lymphoma, Non-Hodgkin 22Lymphoma, Large B-Cell, Diffuse 22Stomach Neoplasms 21Sarcoma, Ewing 21Lung Neoplasms 19Leukemia, Myeloid, Acute 19Leukemia 19

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Vaccinia × Sarcoma × Clear all
NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Transgene

Phase 1/2 Terminated
31 enrolled
BreastDermatologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡